After decades wait for RSV vaccine, two come along at once

Scientists at the US Food and Drug Administration have  outlined a positive stance towards an RSV vaccine developed by Pfizer (NYSE: PFE), ahead of a formal meeting to discuss the firm’s regulatory submission for the candidate.

An earlier panel discussion offered a positive verdict on the product’s use in older adults. The present committee meeting will focus on its use to protect infants.

Should the New York-based pharma major win the agency’s ultimate approval, RSVpreF would become only the second such vaccine to be approved for this kind of viral infection, after GSK’s (LSE: GSK) Arexvy.